Total Payments
$8,341
2024 Payments
$1,338
Companies
71
Transactions
426
Medicare Patients
7,193
Medicare Billing
$3.3M
Payment Breakdown by Category
Food & Beverage$7,664 (91.9%)
Travel$367.16 (4.4%)
Education$309.56 (3.7%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $7,664 | 405 | 91.9% |
| Travel and Lodging | $367.16 | 2 | 4.4% |
| Education | $309.56 | 19 | 3.7% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $524.18 | 31 | $0 (2024) |
| PFIZER INC. | $522.01 | 29 | $0 (2024) |
| Stryker Corporation | $519.06 | 5 | $0 (2021) |
| Amgen Inc. | $441.83 | 23 | $0 (2023) |
| AstraZeneca Pharmaceuticals LP | $411.50 | 25 | $0 (2024) |
| Genentech USA, Inc. | $392.79 | 25 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $391.31 | 26 | $0 (2023) |
| Seagen Inc. | $298.43 | 20 | $0 (2023) |
| Merck Sharp & Dohme LLC | $271.96 | 14 | $0 (2024) |
| GENZYME CORPORATION | $249.03 | 12 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $1,338 | 60 | PFIZER INC. ($260.01) |
| 2023 | $993.70 | 44 | Smith+Nephew, Inc. ($148.54) |
| 2022 | $718.99 | 33 | ASD Specialty Healthcare, LLC ($139.87) |
| 2021 | $1,236 | 55 | Stryker Corporation ($519.06) |
| 2020 | $352.77 | 21 | Seagen Inc. ($69.95) |
| 2019 | $1,110 | 56 | Amgen Inc. ($137.56) |
| 2018 | $997.78 | 61 | Janssen Biotech, Inc. ($107.64) |
| 2017 | $1,593 | 96 | E.R. Squibb & Sons, L.L.C. ($190.70) |
All Payment Transactions
426 individual payment records from CMS Open Payments — Page 1 of 18
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/27/2024 | Takeda Pharmaceuticals U.S.A., Inc. | FRUZAQLA (Drug) | Food and Beverage | In-kind items and services | $25.02 | General |
| Category: ONCOLOGY | ||||||
| 12/20/2024 | GlaxoSmithKline, LLC. | OJJAARA (Drug) | Food and Beverage | In-kind items and services | $23.36 | General |
| Category: ONCOLOGY | ||||||
| 12/19/2024 | Genentech USA, Inc. | Columvi (Biological), Lunsumio, Polivy | Food and Beverage | In-kind items and services | $19.88 | General |
| Category: BioOncology | ||||||
| 12/17/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological), WELIREG | Food and Beverage | In-kind items and services | $23.91 | General |
| Category: ONCOLOGY | ||||||
| 12/16/2024 | Incyte Corporation | JAKAFI (Drug) | Food and Beverage | Cash or cash equivalent | $18.23 | General |
| Category: Hematology/Oncology | ||||||
| 12/13/2024 | Daiichi Sankyo Inc. | Enhertu (Drug) | Food and Beverage | In-kind items and services | $27.18 | General |
| Category: ONCOLOGY | ||||||
| 12/10/2024 | Regeneron Healthcare Solutions, Inc. | LIBTAYO (Biological) | Education | In-kind items and services | $17.02 | General |
| Category: ONCOLOGY | ||||||
| 12/05/2024 | PFIZER INC. | INLYTA (Drug), PADCEV | Food and Beverage | In-kind items and services | $19.76 | General |
| Category: ONCOLOGY | ||||||
| 11/22/2024 | Novartis Pharmaceuticals Corporation | LUTATHERA (Drug) | Food and Beverage | In-kind items and services | $22.57 | General |
| Category: Oncology | ||||||
| 11/18/2024 | Merck Sharp & Dohme LLC | WELIREG (Drug) | Education | In-kind items and services | $18.09 | General |
| Category: ONCOLOGY | ||||||
| 11/14/2024 | GENZYME CORPORATION | CABLIVI (Biological) | Food and Beverage | In-kind items and services | $23.97 | General |
| Category: Hematology | ||||||
| 11/11/2024 | Alexion Pharmaceuticals, Inc. | ULTOMIRIS (Biological) | Food and Beverage | In-kind items and services | $17.12 | General |
| Category: Rare Disease | ||||||
| 11/05/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $30.06 | General |
| Category: ONCOLOGY | ||||||
| 11/01/2024 | Regeneron Healthcare Solutions, Inc. | LIBTAYO (Biological) | Food and Beverage | In-kind items and services | $29.96 | General |
| Category: ONCOLOGY | ||||||
| 10/29/2024 | Daiichi Sankyo Inc. | Enhertu (Drug) | Food and Beverage | In-kind items and services | $18.54 | General |
| Category: ONCOLOGY | ||||||
| 10/22/2024 | ADC Therapeutics America, Inc. | — | Food and Beverage | In-kind items and services | $23.38 | General |
| 10/18/2024 | PFIZER INC. | BRAFTOVI (Drug), MEKTOVI | Education | In-kind items and services | $13.04 | General |
| Category: ONCOLOGY | ||||||
| 10/18/2024 | ARRAY BIOPHARMA INC | BRAFTOVI (Drug), MEKTOVI, TUKYSA | Food and Beverage | In-kind items and services | $7.02 | General |
| Category: ONCOLOGY | ||||||
| 10/18/2024 | ARRAY BIOPHARMA INC | BRAFTOVI (Drug), MEKTOVI, TUKYSA | Food and Beverage | In-kind items and services | $0.71 | General |
| Category: ONCOLOGY | ||||||
| 10/17/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $20.23 | General |
| 10/11/2024 | Eisai Inc. | Lenvima (Drug) | Food and Beverage | In-kind items and services | $23.47 | General |
| Category: Oncology | ||||||
| 10/03/2024 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $15.82 | General |
| 10/01/2024 | AstraZeneca Pharmaceuticals LP | ENHERTU (Biological) | Food and Beverage | In-kind items and services | $22.73 | General |
| Category: Oncology | ||||||
| 09/23/2024 | ABBVIE INC. | VENCLEXTA (Drug) | Food and Beverage | In-kind items and services | $26.24 | General |
| Category: ONCOLOGY | ||||||
| 09/21/2024 | BeiGene USA, Inc. | BRUKINSA (Drug) | Food and Beverage | In-kind items and services | $23.35 | General |
| Category: Oncology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 40 | 1,910 | 34,560 | $2.7M | $871,747 |
| 2022 | 42 | 1,956 | 57,214 | $2.7M | $931,732 |
| 2021 | 39 | 1,673 | 52,719 | $2.1M | $824,054 |
| 2020 | 34 | 1,654 | 40,259 | $2.1M | $682,339 |
Total Patients
7,193
Total Services
184,752
Medicare Billing
$3.3M
Procedure Codes
155
All Medicare Procedures & Services
155 procedure records from CMS Medicare Utilization — Page 1 of 7
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J9271 | Injection, pembrolizumab, 1 mg | Office | 2023 | 16 | 9,800 | $1.1M | $406,429 | 37.7% |
| J0897 | Injection, denosumab, 1 mg | Office | 2023 | 25 | 10,140 | $446,160 | $175,513 | 39.3% |
| J1437 | Injection, ferric derisomaltose, 10 mg | Office | 2023 | 52 | 6,200 | $403,000 | $95,648 | 23.7% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 191 | 670 | $174,200 | $60,954 | 35.0% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 231 | 409 | $68,712 | $24,153 | 35.2% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2023 | 95 | 231 | $121,275 | $23,028 | 19.0% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | Office | 2023 | 412 | 1,169 | $31,563 | $8,864 | 28.1% |
| J1454 | Injection, fosnetupitant 235 mg and palonosetron 0.25 mg | Office | 2023 | 15 | 24 | $31,800 | $7,504 | 23.6% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 20 | 56 | $21,056 | $7,068 | 33.6% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 51 | 51 | $21,879 | $5,884 | 26.9% |
| G0498 | Chemotherapy administration, intravenous infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community setting (e.g., home, domiciliary, rest home or assisted l | Office | 2023 | 19 | 34 | $18,700 | $5,828 | 31.2% |
| J9395 | Injection, fulvestrant, 25 mg | Office | 2023 | 14 | 780 | $62,400 | $5,487 | 8.8% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2023 | 76 | 104 | $24,440 | $5,010 | 20.5% |
| J0885 | Injection, epoetin alfa, (for non-esrd use), 1000 units | Office | 2023 | 13 | 730 | $18,250 | $3,874 | 21.2% |
| 96401 | Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | Office | 2023 | 15 | 70 | $18,200 | $3,868 | 21.3% |
| 96367 | Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | Office | 2023 | 54 | 168 | $19,824 | $3,666 | 18.5% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 89 | 310 | $18,600 | $3,281 | 17.6% |
| 96417 | Administration of additional new drug or substance into vein, 1 hour or less | Office | 2023 | 30 | 63 | $15,750 | $3,122 | 19.8% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 23 | 23 | $10,927 | $3,063 | 28.0% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 17 | 17 | $9,248 | $2,864 | 31.0% |
| 99195 | Drawing of blood for a medical problem | Office | 2023 | 22 | 45 | $11,250 | $2,799 | 24.9% |
| 96402 | Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | Office | 2023 | 23 | 95 | $11,970 | $2,480 | 20.7% |
| 96415 | Administration of chemotherapy into vein, each additional hour | Office | 2023 | 32 | 107 | $14,017 | $2,321 | 16.6% |
| 96375 | Injection of additional new drug or substance into vein | Office | 2023 | 59 | 176 | $14,432 | $2,084 | 14.4% |
| 96411 | Administration of additional new drug or substance into vein using push technique | Office | 2023 | 18 | 27 | $5,886 | $1,154 | 19.6% |
About Dr. Jay Rhee, M.D
Dr. Jay Rhee, M.D is a Hematology & Oncology healthcare provider based in Atlanta, Georgia. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/28/2006. The National Provider Identifier (NPI) number assigned to this provider is 1568490852.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Jay Rhee, M.D has received a total of $8,341 in payments from pharmaceutical and medical device companies, with $1,338 received in 2024. These payments were reported across 426 transactions from 71 companies. The most common payment nature is "Food and Beverage" ($7,664).
As a Medicare-enrolled provider, Rhee has provided services to 7,193 Medicare beneficiaries, totaling 184,752 services with total Medicare billing of $3.3M. Data is available for 4 years (2020–2023), covering 155 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Location Atlanta, GA
- Active Since 06/28/2006
- Last Updated 08/08/2024
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1568490852
Products in Payments
- EVEREST SPINAL SYSTEM (Device) $519.06
- TUKYSA (Drug) $326.68
- OPDIVO (Biological) $255.16
- KEYTRUDA (Biological) $253.87
- IBRANCE (Drug) $253.28
- IMBRUVICA (Drug) $248.22
- XARELTO (Drug) $180.71
- Lenvima (Drug) $156.00
- ADCETRIS (Biological) $152.33
- Enhertu (Drug) $145.92
- Nplate (Biological) $139.79
- LIBTAYO (Biological) $136.58
- JAKAFI (Drug) $128.77
- ECHELON FLEX Stapler (Device) $114.25
- ENHERTU (Biological) $109.75
- Kyprolis (Biological) $103.65
- VENCLEXTA (Drug) $101.58
- LYNPARZA (Drug) $97.57
- SARCLISA (Biological) $87.90
- STRAVIX (Medical Supply) $86.44
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Atlanta
Dr. Jonathon Cohen, M.d, M.D
Hematology & Oncology — Payments: $330,523
Hematology & Oncology $330,523
Dr. Ajay Nooka, M.d., M.p.h.,F.a.c.p, M.D., M.P.H.,F.A.C.P
Hematology & Oncology — Payments: $256,358
Hematology & Oncology $256,358
Dr. Rodolfo Bordoni, Md, MD
Hematology & Oncology — Payments: $240,507
Hematology & Oncology $240,507
Dr. Mehmet Bilen, M.d, M.D
Hematology & Oncology — Payments: $134,196
Hematology & Oncology $134,196
Olatunji Alese, M.d, M.D
Hematology & Oncology — Payments: $131,083
Hematology & Oncology $131,083
Dr. Carlos Franco, Md, MD
Hematology & Oncology — Payments: $115,439
Hematology & Oncology $115,439